Anixa Biosciences (NASDAQ:ANIX - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01, Zacks reports.
Anixa Biosciences Trading Down 1.1%
NASDAQ ANIX traded down $0.03 during trading on Wednesday, reaching $2.79. The company's stock had a trading volume of 69,665 shares, compared to its average volume of 90,479. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $4.20. The firm has a 50 day moving average price of $2.67 and a 200 day moving average price of $2.80. The firm has a market capitalization of $89.87 million, a price-to-earnings ratio of -7.15 and a beta of 0.34.
Analyst Ratings Changes
A number of research firms have commented on ANIX. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Thursday, May 29th. Maxim Group assumed coverage on shares of Anixa Biosciences in a report on Friday, March 21st. They issued a "buy" rating and a $10.00 price target on the stock. Finally, HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a report on Tuesday, March 25th.
Read Our Latest Research Report on Anixa Biosciences
About Anixa Biosciences
(
Get Free Report)
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
See Also
Before you consider Anixa Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anixa Biosciences wasn't on the list.
While Anixa Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
